Soligenix Inc (Nasdaq: SNGX), a late-stage biopharmaceutical company, has completed enrolment of its patients in its phase three DOM-INNATE study for SGX942 (dusquetide) intended to treat oral mucositis in head and neck cancer patients, it was reported on Wednesday.
The study enrolled 268 subjects based on positive interim analysis that included an assessment of the study's primary efficacy endpoint by an independent Data Monitoring Committee. The top-line results of the study are likely to be revealed in the fourth quarter of 2020.
The product is a novel, first-in-class, Innate Defense Regulator that modulates inflammation and improves the innate immune system's anti-infective and tissue-healing pathways.
NeoImmuneTech names new president and chief executive officer
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
Thermo Fisher Scientific unveils CorEvitas registry for generalized pustular psoriasis
Nektar Therapeutics commences Phase 2b rezpegaldesleukin clinical trial for alopecia areata
Innovent Biologics doses first participant in first-in-human phase one clinical trial of IBI3002
Ananda Developments secures CBD Drug Supply Agreement for endometriosis clinical trial
Trellus Health secures agreement with major US health plan for IBD management
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins